Ligand ID: PZI


Drugbank ID:
DB09210
(Piracetam)


Indication:
For the treatment of myoclonus (brief, involuntary twitching of a muscle or a group of muscles).

Get human targets for PZI in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'PZI'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		1q2w 3C-LIKE PROTEASE
(SARSr-CoV)		3 / 3
PRO B 122
SER B 123
ASN B  28
1.67A20.57
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB800_0
(GLUTAMATE RECEPTOR 2)		1uk4 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 10
TYR B 118
LEU B 141
PRO B 168
SER B 139
GLY B 170
1.60A20.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		1wof 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
ILE A 281
SER A   1
GLY A 283
ASN A 214
1.14A20.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.65A20.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		2a5k 3C-LIKE PEPTIDASE
(SARSr-CoV)		3 / 3
PRO B 122
SER B 123
ASN B  28
1.63A20.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		2acf REPLICASE
POLYPROTEIN 1AB
(SARS-COV
Tor2)		3 / 3
ASP D 352
ASN D 353
SER A 266
1.41A21.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		2ajf ACE2
(Homo
sapiens)		4 / 7
TYR B 183
MET B 123
ASN B 121
LEU B 120
1.79A18.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		2ajf ACE2
(Homo
sapiens)		4 / 8
ILE B 256
PRO B 263
SER B 607
PRO B 612
1.33A18.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		2ajf ACE2
(Homo
sapiens)		4 / 8
TYR B 158
PRO B 492
SER B 611
ASP B 615
1.51A17.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		2ajf ACE2
SPIKE PROTEIN
(Homo
sapiens;
SARSr-CoV)		4 / 8
TYR F 442
PRO F 459
SER F 461
LYS B  31
1.29A18.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		2ajf ACE2
(Homo
sapiens)		3 / 3
SER A  70
ASP A  67
ASN A  63
1.67A17.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		2amd 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
PRO B 122
SER B 123
ASN B  28
1.52A20.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		4 / 8
PRO D 303
LEU D 292
ASP D 289
LYS D 356
1.45A17.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE800_0
(GLUTAMATE RECEPTOR 2)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		5 / 10
SER C 319
GLY C 336
PRO C 310
SER D 319
LYS C 262
1.79A17.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB800_0
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 10
PRO B  74
MET B  57
SER B  72
SER B  54
LEU B  55
1.59A20.55
None
None
None
None
D10  B1099 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 8
PRO F  74
MET F  57
SER F  72
SER F  54
LEU F  55
1.54A16.59
None
None
None
None
D10  F1099 ( 4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 8
PRO B  74
MET B  57
SER B  72
SER B  54
LEU B  55
1.55A20.55
None
None
None
None
D10  B1099 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 8
PRO A  74
MET A  57
SER A  72
SER A  54
LEU A  55
1.56A20.09
None
None
None
None
D10  B1099 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB800_0
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 10
PRO A  74
MET A  57
SER A  72
SER A  54
LEU A  55
1.61A20.09
None
None
None
None
D10  B1099 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE800_0
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 10
PRO B  74
MET B  57
SER B  72
SER B  54
LEU B  55
1.60A20.55
None
None
None
None
D10  B1099 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE800_0
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 10
PRO A  74
MET A  57
SER A  72
SER A  54
LEU A  55
1.61A20.09
None
None
None
None
D10  B1099 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		2cme -
(-)		5 / 8
PRO E  74
MET E  57
SER E  72
SER E  54
LEU E  55
1.57A19.63
None
None
None
None
D10  F1099 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE800_0
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 10
PRO F  74
MET F  57
SER F  72
SER F  54
LEU F  55
1.59A16.59
None
None
None
None
D10  F1099 ( 4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE800_0
(GLUTAMATE RECEPTOR 2)		2cme -
(-)		5 / 10
PRO E  74
MET E  57
SER E  72
SER E  54
LEU E  55
1.62A19.63
None
None
None
None
D10  F1099 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB800_0
(GLUTAMATE RECEPTOR 2)		2cme -
(-)		5 / 10
PRO E  74
MET E  57
SER E  72
SER E  54
LEU E  55
1.62A19.63
None
None
None
None
D10  F1099 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB800_0
(GLUTAMATE RECEPTOR 2)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		5 / 10
PRO F  74
MET F  57
SER F  72
SER F  54
LEU F  55
1.59A16.59
None
None
None
None
D10  F1099 ( 4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		2dd8 SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
SER S 456
ASP S 454
ASN S 409
1.33A18.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		2dd8 IGG HEAVY CHAIN
(Homo
sapiens)		3 / 3
PRO H 119
SER H 203
ASN H 199
1.55A23.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		3 / 3
ASP B  77
ASN B 157
SER A  79
1.33A21.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		3 / 3
SER A  79
ASP B  77
ASN B 157
1.17A22.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		2ga6 ORF1A POLYPROTEIN
(SARSr-CoV)		4 / 8
ILE G  81
SER G  15
SER J  15
SER D  15
1.21A18.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		2ghv SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
SER C 456
ASP C 454
ASN C 409
1.52A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB800_0
(GLUTAMATE RECEPTOR 2)		2ghv SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
TYR E 338
PRO E 459
LEU E 478
ASP E 480
PRO E 469
1.64A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		2ghv SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
SER E 353
SER C 370
LEU C 374
ASP C 376
1.29A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		3 / 3
SER D 224
ASP C 480
ASN C 479
1.49A20.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB800_0
(GLUTAMATE RECEPTOR 2)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 10
TYR B 168
PRO B 228
LEU B 104
SER B 101
GLY A 434
1.66A20.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		2ghw ANTI-SCFV ANTIBODY,
80R
(Homo
sapiens)		4 / 7
TYR B 168
LEU B 104
ASP B 105
SER B 101
1.18A20.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE800_0
(GLUTAMATE RECEPTOR 2)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 10
PRO A 469
GLY B 198
PRO A 459
LEU A 478
ASP A 480
1.55A19.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		2ghw SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
ASN A 381
LEU A 504
LYS C 318
SER A 346
1.61A19.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		2ghw ANTI-SCFV ANTIBODY,
80R
(Homo
sapiens)		4 / 8
TYR D 168
PRO D 228
LEU D 104
ASP D 105
1.37A20.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 8
PRO A 469
SER B 199
SER B 163
GLY B 198
PRO A 459
1.67A19.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		3 / 3
ASP A 323
ASN A  74
SER A 197
0.93A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		2kqv NSP3
(SARSr-CoV)		4 / 7
TYR A  61
ASN A  75
LEU A  74
SER A 104
1.64A23.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		2kys NSP7
(SARSr-CoV)		4 / 7
ASN A  39
LEU A  43
ASP A  40
SER A   6
1.38A14.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		2op9 REPLICASE
POLYPROTEIN 1AB
(PP1AB, ORF1AB)
3C-LIKE PROTEINASE
(3CL-PRO, 3CLP)
(SARSr-CoV)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.67A20.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 8
ILE C 327
SER A 241
GLY A 243
ASN C  74
1.20A23.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		3 / 3
ASP D 323
ASN D  74
SER D 197
0.87A23.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		2q6g REPLICASE
POLYPROTEIN 1AB
(SARS-COV
BJ01)		3 / 3
PRO B 122
SER B 123
ASN B  28
1.61A20.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		2qc2 3C-LIKE PROTEINASE
(-)		3 / 3
PRO B 122
SER B 123
ASN B  28
1.66A20.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		2qiq REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.67A20.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 8
SER F 288
GLY F 286
PRO D  65
ASN D 163
0.97A22.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		3 / 3
ASP A 323
ASN A  74
SER A 197
0.85A22.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		3 / 3
SER B 197
ASP B 323
ASN B  74
0.94A22.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		2vj1 MAIN PROTEINASE
(SARSr-CoV)		3 / 3
PRO B 122
SER B 123
ASN B  28
1.54A20.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		2w2g NSP3
(SARSr-CoV)		3 / 3
PRO B 442
SER A 585
ASN B 418
1.54A21.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE800_0
(GLUTAMATE RECEPTOR 2)		2wct NSP3
(SARSr-CoV)		5 / 10
PRO C 588
SER C 591
SER C 461
ASP C 416
LYS B 586
1.53A21.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		3 / 3
PRO A  37
SER A 241
ASN A  33
1.33A22.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		2xyr NSP10
PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		3 / 3
PRO A  80
SER A  74
ASN B  40
1.18A22.70
SFG  A1298 (-3.7A)
SFG  A1298 ( 4.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		3atw 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.58A18.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG800_0
(GLUTAMATE RECEPTOR 2)		3bgf SPIKE PROTEIN S1
(SARSr-CoV)		4 / 6
TYR S 338
ASN A 479
LEU S 478
ASP S 480
1.72A18.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB800_0
(GLUTAMATE RECEPTOR 2)		3bgf SPIKE PROTEIN S1
(SARSr-CoV)		5 / 10
TYR A 338
PRO A 459
LEU A 478
ASP A 480
PRO A 469
1.68A18.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		3bgf F26G19 FAB
(Mus
musculus)		5 / 8
ILE H 212
SER H 182
GLY H 141
PRO H 126
SER L 116
1.78A20.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		3bgf F26G19 FAB
(Mus
musculus)		3 / 3
PRO H  14
SER H 113
ASN H  84
1.06A20.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		3bgf SPIKE PROTEIN S1
(SARSr-CoV)		4 / 7
TYR S 338
ASN A 479
LEU S 478
ASP S 480
1.68A18.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		3bgf SPIKE PROTEIN S1
(SARSr-CoV)		3 / 3
SER S 456
ASP S 454
ASN S 409
1.41A18.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		3bgf F26G19 FAB
(Mus
musculus)		4 / 8
TYR B 147
PRO B 169
SER B 180
LEU B 179
1.36A21.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		3bgf F26G19 FAB
(Mus
musculus)		4 / 8
SER C 162
SER C 176
SER B 180
ASN C 137
1.24A23.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		3 / 3
SER B  70
ASP B  67
ASN B  63
1.66A17.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		3d0g SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
SER E 456
ASP E 454
ASN E 409
1.47A17.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 7
TYR A 202
ASN A 103
LYS A 187
SER A 106
1.62A17.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		3d0i SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
SER E 456
ASP E 454
ASN E 409
1.44A18.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		3d62 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.68A20.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		3e91 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
PRO B 122
SER B 123
ASN B  28
1.63A20.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		3ee7 REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		4 / 7
TYR C  89
ASN C  27
LEU C  51
LYS C  52
1.70A18.85
None
None
None
GOL  C 124 (-2.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG800_0
(GLUTAMATE RECEPTOR 2)		3ee7 REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		4 / 6
TYR C  89
ASN C  27
LEU C  51
LYS C  52
1.65A18.85
None
None
None
GOL  C 124 (-2.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		3f9f 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
PRO B 122
SER B 123
ASN B  28
1.58A19.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		3f9g 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
PRO B 122
SER B 123
ASN B  28
1.62A19.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		3f9h 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
TYR B 126
PRO B 122
SER B 123
SER B 144
1.58A19.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		3iwm 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
PRO B 122
SER B 123
ASN B  28
1.38A20.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		3m3s 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
PRO B 122
SER B 123
ASN B  28
1.59A20.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE800_0
(GLUTAMATE RECEPTOR 2)		3m3t 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 10
SER A 121
GLY A 120
SER A 123
SER A 144
LEU A 141
1.68A20.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		3m3t 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.63A20.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		3m3v 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.63A20.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		3r24 2'-O-METHYL
TRANSFERASE
NSP10 AND NSP11
(SARSr-CoV)		3 / 3
PRO A  80
SER A  74
ASN B  40
1.22A22.06
SAM  A 302 (-3.8A)
SAM  A 302 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		3sci ACE2
(Homo
sapiens)		4 / 7
TYR B 202
ASN B 103
LYS B 187
SER B 106
1.67A18.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		3scj ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		4 / 8
TYR F 442
PRO F 459
SER F 461
LYS B  31
1.37A18.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 7
TYR B 183
MET B 123
ASN B 121
LEU B 120
1.78A17.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		3 / 3
SER B 511
ASP B 206
ASN B 397
1.54A17.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 8
ILE B 256
PRO B 263
SER B 607
PRO B 612
1.31A17.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 8
TYR B 158
PRO B 492
SER B 611
ASP B 615
1.45A17.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		4hi3 3C-LIKE PROTEINASE
(SARSr-CoV)		3 / 3
PRO B 122
SER B 123
ASN B  28
1.66A20.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		4m0w REPLICASE
POLYPROTEIN 1A
UBIQUITIN
(Bos
taurus;
SARSr-CoV)		4 / 8
TYR A 274
PRO A 248
SER A 246
LEU B  73
1.58A21.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 8
ILE D 164
SER D 230
GLY D 232
SER D 171
1.32A18.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		3 / 3
PRO D 106
SER D 194
ASN D 104
1.41A18.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 8
ILE D 164
SER D 230
GLY D 232
SER D 171
1.29A18.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		4 / 8
ILE B 299
GLY B 300
PRO B 297
ASN B 422
1.22A18.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		5r7z 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.68A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
SER A 123
ASN A  28
SER A 147
GLY A 143
1.63A20.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
SER A 147
GLY A 143
SER A 123
ASN A  28
1.63A20.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.72A20.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		5tl6 REPLICASE
POLYPROTEIN 1AB
UBIQUITIN-LIKE
PROTEIN ISG15
(Homo
sapiens;
SARSr-CoV)		4 / 8
TYR D 274
PRO D 248
SER D 246
LEU C 154
1.56A22.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
SER B 798
ASP B 802
ASN B 806
1.23A12.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ASP B 802
ASN B 806
SER B 798
1.40A13.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		5x4r S PROTEIN
(MERS-CoV)		4 / 7
ASN A 226
LEU A 225
ASP A 174
SER A 227
1.78A20.93
NAG  A 503 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		5x4r S PROTEIN
(MERS-CoV)		4 / 8
SER A 106
GLY A 162
PRO A 196
SER A 203
1.26A20.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 8
PRO C 540
SER C 541
SER C 574
ASP C 560
1.60A12.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		3 / 3
PRO B 565
SER B 568
ASN B 318
1.55A12.87
None
None
NAG  B1308 (-2.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		5x59 S PROTEIN
(MERS-CoV)		4 / 7
TYR B 794
ASN B1028
ASP B1024
LYS B1021
1.26A11.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG800_0
(GLUTAMATE RECEPTOR 2)		5x59 S PROTEIN
(MERS-CoV)		4 / 6
TYR B 794
ASN B1028
ASP B1024
LYS B1021
1.22A11.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		5x59 S PROTEIN
(MERS-CoV)		4 / 8
SER A 106
GLY A 162
PRO A 196
SER A 203
1.26A11.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE800_0
(GLUTAMATE RECEPTOR 2)		5x59 S PROTEIN
(MERS-CoV)		5 / 10
PRO B 767
SER C 858
SER C 954
SER C 965
LEU C 964
1.66A11.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 7
LEU B 948
ASP A 557
LYS B 946
SER B 957
1.54A12.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		5x5c S PROTEIN
(MERS-CoV)		4 / 8
PRO A 742
SER A 761
SER A 734
LEU A 735
1.52A11.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		5x5f S PROTEIN
(MERS-CoV)		3 / 3
ASP C 644
ASN C 647
SER C 598
1.15A11.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		5x5f S PROTEIN
(MERS-CoV)		3 / 3
SER C 598
ASP C 644
ASN C 647
1.00A11.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
PRO C 586
SER C 592
LEU C 286
LYS C 287
1.52A12.95
PRO  C 586 ( 1.1A)
SER  C 592 ( 0.0A)
LEU  C 286 ( 0.6A)
LYS  C 287 ( 0.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ILE A 694
PRO C 879
PRO A1061
ASN A1080
1.00A13.04
ILE  A 694 ( 0.7A)
PRO  C 879 ( 1.1A)
PRO  A1061 ( 1.1A)
ASN  A1080 ( 0.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
TYR B 356
LEU B 374
ASP B 376
SER A 964
1.68A13.04
TYR  B 356 ( 1.3A)
LEU  B 374 ( 0.6A)
ASP  B 376 ( 0.6A)
SER  A 964 ( 0.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG800_0
(GLUTAMATE RECEPTOR 2)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
TYR B 481
ASN B 409
ASP B 393
LYS B 390
1.64A13.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
TYR B 481
ASN B 409
ASP B 393
LYS B 390
1.58A13.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
PRO C 586
SER C 592
ASN C 589
1.65A13.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB800_0
(GLUTAMATE RECEPTOR 2)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
TYR A  53
SER A 950
ASP B 557
SER A 957
GLY A 953
1.61A12.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
TYR C 356
SER C 370
LEU C 374
ASP C 376
1.33A12.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6acg ACE2
(Homo
sapiens)		3 / 3
SER D  70
ASP D  67
ASN D  64
1.56A17.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG800_0
(GLUTAMATE RECEPTOR 2)		6acg ACE2
(Homo
sapiens)		4 / 6
TYR D 183
MET D 123
ASN D 121
LEU D 120
1.80A18.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6acg ACE2
(Homo
sapiens)		3 / 3
ASP D 543
ASN D 546
SER D 411
1.21A18.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6acg ACE2
(Homo
sapiens)		4 / 8
TYR D 158
PRO D 492
SER D 611
ASP D 615
1.33A17.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ILE A 694
PRO C 879
PRO A1061
ASN A1080
1.21A13.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
SER A 798
ASP A 802
ASN A 806
1.18A12.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ASP A 802
ASN A 806
SER A 798
1.28A13.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE800_0
(GLUTAMATE RECEPTOR 2)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
PRO B 210
SER B 211
GLY B 212
SER B  36
LEU B  60
1.80A12.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 8
PRO C 586
SER C 592
LEU C 286
LYS C 287
1.52A12.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
ASP A 802
ASN A 806
SER A 798
1.15A12.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
PRO B 513
SER B 516
ASN B 375
1.13A13.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
SER A 798
ASP A 802
ASN A 806
1.12A11.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		3 / 3
ASP C 802
ASN C 806
SER C 798
1.14A13.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB800_0
(GLUTAMATE RECEPTOR 2)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
TYR C 338
PRO C 459
LEU C 478
ASP C 480
PRO C 469
1.68A11.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE800_0
(GLUTAMATE RECEPTOR 2)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
SER A 740
GLY A 739
SER C 949
LEU C 948
ASP B 557
1.64A11.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 7
TYR A 352
LEU A 377
ASP A 376
LYS A 371
1.43A13.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 8
PRO B 240
SER B 248
GLY B 246
ASN B  73
1.33A13.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 8
TYR B 352
LEU B 377
ASP B 376
LYS B 373
1.30A11.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6cs2 ACE2
(Homo
sapiens)		3 / 3
SER D 511
ASP D 206
ASN D 397
1.70A18.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG800_0
(GLUTAMATE RECEPTOR 2)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 6
TYR B 352
LEU B 377
ASP B 376
LYS B 373
1.37A13.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6jyt HELICASE
(SARSr-CoV)		3 / 3
SER B   0
ASP A  56
ASN B  46
1.51A18.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6jyt HELICASE
(SARSr-CoV)		3 / 3
ASP A  56
ASN B  46
SER B   0
1.53A17.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6lze VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.71A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6lze VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A 119
1.79A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A 119
1.76A21.86
None
DMS  A 403 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.69A21.86
None
DMS  A 403 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		4 / 8
PRO C 493
SER C 491
SER C 487
GLY C 490
1.32A17.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m17 RECEPTOR BINDING
DOMAIN
(SARS-CoV-2)		3 / 3
PRO F 507
SER F 438
ASN F 448
1.33A20.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		4 / 8
PRO A 109
SER A 106
LEU A 101
ASP A 445
1.43A16.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		4 / 7
MET C 119
LEU C 101
ASP C 445
SER C 288
1.56A17.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6m1d ACE2
(Homo
sapiens)		3 / 3
ASP B 543
ASN B 546
SER B 411
0.93A15.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB800_0
(GLUTAMATE RECEPTOR 2)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 10
TYR C 231
SER C 431
LEU C  46
SER C 280
GLY C 434
1.67A16.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		6m1d ACE2
(Homo
sapiens)		4 / 7
ASN D 712
LEU D 722
ASP D 719
SER D 709
1.31A15.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER D  10
SER B  10
GLY D  11
PRO D 122
1.60A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PRO A 122
SER A  10
ILE C 152
SER C  10
1.53A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER D 121
ILE B 152
PRO B   9
SER D 123
1.50A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PRO D 122
SER D  10
SER B  10
GLY D  11
1.67A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PRO B   9
GLY D 124
PRO D 122
SER D 147
1.63A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER A  10
SER C  10
GLY A  11
PRO A 122
1.68A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
PRO B 122
SER B 123
ASN B 119
1.63A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
PRO B 122
SER B 123
ASN B  28
1.54A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A 119
1.60A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ILE B 152
PRO B   9
SER D 123
SER D 121
1.48A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.52A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PRO B 122
SER B  10
ILE D 152
SER D  10
1.50A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER C  10
SER A  10
GLY C  11
PRO C 122
1.61A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
TYR A 126
PRO A 122
SER A 123
SER A 147
1.79A22.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PRO A   9
GLY C 124
PRO C 122
SER C 147
1.61A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ILE C 152
SER C  10
PRO A 122
SER A  10
1.56A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
PRO C 122
SER C 123
ASN C  28
1.70A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER C 123
ASN C  28
SER C 147
GLY C 143
1.67A22.12

None
None
None
3WL  C 401 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ILE D 152
SER D  10
PRO B 122
SER B  10
1.53A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER B  10
SER D  10
GLY B  11
PRO B 122
1.65A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
PRO D 122
SER D 123
ASN D  28
1.70A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER A 123
ASN A  28
SER A 147
GLY A 143
1.64A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m2q 3CL PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.73A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER A 147
GLY A 143
SER A 123
ASN A  28
1.65A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ILE A 201
SER A 229
GLY A 200
PRO A 232
1.53A14.77

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 8
MET A 633
SER A 635
LEU A 308
ASP A 304
1.62A14.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID800_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 7
ASN B 109
LEU A 271
ASP A 269
LYS A 272
1.69A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ILE A 536
PRO A 537
SER A 343
PRO A 378
1.57A14.77

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG800_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 6
ASN B 109
LEU A 271
ASP A 269
LYS A 272
1.68A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 7
ASN B 109
LEU A 271
ASP A 269
LYS A 272
1.66A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 8
PRO A 232
ILE A 201
SER A 229
GLY A 200
1.52A14.77

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 7
ASN A 312
LEU A 469
ASP A 465
SER A 239
1.73A14.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ILE A 201
GLY A 230
PRO A 227
ASN A 198
1.51A14.77

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 8
PRO A 227
ASN A 198
ILE A 201
GLY A 230
1.50A14.77

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID800_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 7
SER A 239
ASN A 312
LEU A 469
ASP A 465
1.75A14.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 8
PRO A 537
PRO A 328
SER A 664
GLY A 327
1.64A14.77

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		3 / 3
PRO A 243
SER A 239
ASN A 312
1.51A14.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
SER C 798
ASP C 802
ASN C 806
1.24A12.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
ASP B 312
ASN B 528
SER B 310
1.01A13.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
PRO B 540
SER B 541
SER B 574
ASP B 560
1.42A12.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		3 / 3
PRO C 565
SER C 568
ASN C 318
1.62A13.08
None
NAG  C1320 ( 4.8A)
NAG  C1320 (-1.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
(Homo
sapiens)		4 / 8
PRO H 227
SER H 202
GLY H 204
PRO H 140
1.13A23.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		6nur NSP12
(SARSr-CoV)		4 / 7
ASN A 312
LEU A 469
ASP A 465
SER A 239
1.74A12.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6nur NSP12
(SARSr-CoV)		4 / 8
ILE A 539
PRO A 378
SER A 664
PRO A 537
1.05A12.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG800_0
(GLUTAMATE RECEPTOR 2)		6nus NSP12
(SARSr-CoV)		4 / 6
TYR A 828
LEU A 805
ASP A 804
LYS A 807
1.75A12.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6nus NSP12
(SARSr-CoV)		4 / 8
MET A 633
SER A 635
LEU A 308
ASP A 304
1.58A12.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6nus NSP12
(SARSr-CoV)		3 / 3
PRO A 243
SER A 239
ASN A 312
1.45A12.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
SER C 816
ASP C 820
ASN C 824
1.26A12.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASP B 820
ASN B 824
SER B 816
1.31A12.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PRO C 600
SER C 605
LEU C 296
ASP C 294
1.46A12.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6vw1 ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		3 / 3
ASP A 355
ASN E 501
SER A  44
1.36A18.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6vw1 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
PRO E 521
SER E 393
ASN E 519
1.38A20.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6vxs NSP3
(SARS-CoV-2)		4 / 8
ILE B 131
SER B 128
GLY B 130
ASN B 101
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6vxs NSP3
(SARS-CoV-2)		3 / 3
ASP B 162
ASN B 159
SER B 166
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6vxs NSP3
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A 101
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6vxs NSP3
(SARS-CoV-2)		3 / 3
SER B 166
ASP B 162
ASN B 159
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6vxs NSP3
(SARS-CoV-2)		4 / 8
ASN A 101
ILE A 131
SER A 128
GLY A 130
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6vxs NSP3
(SARS-CoV-2)		4 / 8
ASN B 101
ILE B 131
SER B 128
GLY B 130
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASP C 820
ASN C 824
SER C 813
0.71A12.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PRO A 600
SER A 605
LEU A 296
ASP A 294
1.57A12.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ILE C 587
PRO C 589
GLY C 550
ASN A 978
1.30A12.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
PRO B 579
SER B 530
ASN B 331
1.62A12.70
None
None
NAG  B1305 (-1.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASP A 820
ASN A 824
SER A 813
0.74A12.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
SER C 813
ASP C 820
ASN C 824
0.77A12.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ASP B 324
ASN B  75
SER B 198
0.93A22.10
None
EDO  B 403 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6w02 NSP3
(SARS-CoV-2)		3 / 3
SER A 166
ASP A 162
ASN A 159
1.65A19.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w37 PROTEIN 7A
(SARS-CoV-2)		4 / 8
SER A  21
GLY A  23
PRO A  19
ASN A  37
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w37 PROTEIN 7A
(SARS-CoV-2)		4 / 8
PRO A  19
ASN A  37
SER A  21
GLY A  23
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 8
ILE L  48
SER L  65
GLY L  64
ASN L  31
1.72A20.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PRO C 507
SER C 443
ASN C 437
GLY C 502
1.63A21.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		3 / 3
PRO H 202
SER H 203
ASN H 199
1.60A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PRO C 507
SER C 443
ASN C 501
GLY C 496
1.60A21.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 8
PRO H 126
PRO H 213
SER H 188
GLY H 190
1.44A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		3 / 3
PRO H 119
SER H 203
ASN H 199
1.52A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		3 / 3
ASP L  70
ASN L  22
SER L  67
1.76A20.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 8
PRO H 126
SER H 188
SER H 186
GLY H 190
1.66A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB LIGHT
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		3 / 3
SER L  56
ASP C 389
ASN C 388
1.41A20.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 8
SER H 188
SER H 186
GLY H 190
PRO H 126
1.70A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 8
TYR H 145
PRO H 167
SER H 179
LEU H 178
1.40A19.44
None
None
GOL  L 301 (-3.5A)
GOL  L 301 (-4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 8
ILE H  98
SER H  96
GLY H  97
PRO H 100
1.64A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		3 / 3
SER L  67
ASP L  70
ASN L  22
1.75A20.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PRO H 100
ILE H  98
SER C 383
GLY H  97
1.77A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 8
PRO H 213
SER H 188
GLY H 190
PRO H 126
1.42A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 8
PRO H 213
PRO H 126
SER H 130
SER H 186
1.75A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 8
ILE H  34
PRO H  52
SER H  55
SER H  70
1.53A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
GLY C 496
PRO C 507
SER C 443
ASN C 501
1.54A21.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ILE H  98
SER H  96
SER C 383
GLY H  97
1.61A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 8
PRO H 126
SER H 130
SER H 186
PRO H 213
1.77A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 8
PRO H 100
ILE H  98
SER H  96
GLY H  97
1.65A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ILE H  98
SER H  96
SER C 383
GLY H  97
1.66A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 8
ILE H  34
PRO H  52
SER H  55
SER H  70
1.47A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 8
ILE L  48
SER L  65
SER L  67
ASN L  31
1.80A20.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 8
PRO L 120
SER L 131
SER L 127
ASP H 144
1.68A19.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ILE H  98
SER C 383
GLY H  97
PRO H 100
1.79A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB LIGHT
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		3 / 3
ASP C 389
ASN C 388
SER L  56
1.32A21.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6w4h NSP10
NSP16
(SARS-CoV-2)		3 / 3
PRO A6878
SER A6872
ASN B4293
1.31A20.13
SAM  A7102 (-3.8A)
SAM  A7102 ( 4.5A)
BDF  B4403 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ILE A6838
PRO A6835
SER A7039
SER A7041
1.69A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ILE A6838
PRO A6835
SER A7039
SER A7041
1.69A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		3 / 3
PRO A6878
SER A6872
ASN B4293
1.34A
SAM  A7104 (-3.9A)
SAM  A7104 (-4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ILE A7079
PRO A6860
SER A6964
ASN A7008
1.64A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ASN A7008
ILE A7079
PRO A6860
SER A6964
1.71A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ASN B  99
ILE B 131
SER B 128
GLY B 130
1.53A20.24
None
None
MES  B 201 ( 4.5A)
MES  B 201 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
SER B 128
GLY B 130
PRO B 136
SER B 139
1.58A20.24
MES  B 201 ( 4.5A)
MES  B 201 ( 3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ILE B 131
SER B 128
GLY B 130
ASN B  99
1.58A20.24
None
MES  B 201 ( 4.5A)
MES  B 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
PRO A 136
SER A 139
SER A 128
GLY A 130
1.67A20.24
None
None
None
AMP  A 201 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A  99
1.69A20.24
AMP  A 201 ( 3.6A)
None
AMP  A 201 ( 3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A 101
1.69A20.24
AMP  A 201 ( 3.6A)
None
AMP  A 201 ( 3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ASN A 101
ILE A 131
SER A 128
GLY A 130
1.64A20.24
None
AMP  A 201 ( 3.6A)
None
AMP  A 201 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
SER A 128
GLY A 130
PRO A 136
SER A 139
1.73A20.24
None
AMP  A 201 ( 3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
SER B 128
GLY B 133
PRO B 136
SER B 139
1.71A20.24
MES  B 201 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
PRO B 136
SER B 139
SER B 128
GLY B 133
1.76A20.24
None
None
MES  B 201 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
SER A 128
GLY A 133
PRO A 136
SER A 139
1.76A20.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ASN B 101
ILE B 131
SER B 128
GLY B 130
1.38A20.24
None
None
MES  B 201 ( 4.5A)
MES  B 201 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ILE B 131
SER B 128
GLY B 130
ASN B 101
1.42A20.24
None
MES  B 201 ( 4.5A)
MES  B 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
PRO B 136
SER B 139
SER B 128
GLY B 130
1.52A20.24
None
None
MES  B 201 ( 4.5A)
MES  B 201 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ASN A  99
ILE A 131
SER A 128
GLY A 130
1.65A20.24
None
AMP  A 201 ( 3.6A)
None
AMP  A 201 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ILE C7079
PRO C6860
SER C6964
ASN C7008
1.63A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ILE A6838
PRO A6835
SER A7039
SER A7041
1.69A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ILE A6838
PRO A6835
SER A7039
SER A7041
1.70A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ILE A7079
PRO A6860
SER A6964
ASN A7008
1.64A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ILE C6838
PRO C6835
SER C7039
SER C7041
1.71A18.25
None
None
FMT  C7111 ( 3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP10
NSP16
(SARS-CoV-2)		3 / 3
PRO C6878
SER C6872
ASN D4293
1.26A18.25
SAM  C7105 ( 3.9A)
SAM  C7105 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ILE C6838
PRO C6835
SER C7039
SER C7041
1.70A18.25
None
None
FMT  C7111 ( 3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ASN A7008
ILE A7079
PRO A6860
SER A6964
1.72A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ASN C7008
ILE C7079
PRO C6860
SER C6964
1.71A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP10
NSP16
(SARS-CoV-2)		3 / 3
PRO A6878
SER A6872
ASN B4293
1.29A18.25
SAM  A7102 ( 3.8A)
SAM  A7102 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
TYR B 305
MET B 244
SER B 245
SER B 262
1.67A23.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
TYR A  56
MET A  84
SER A  85
LEU A  80
1.76A23.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
TYR C 251
PRO C 247
SER C 245
LEU C 211
1.80A23.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
TYR C 305
MET C 244
SER C 245
SER C 262
1.69A23.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
TYR A 305
MET A 244
SER A 245
SER A 262
1.64A23.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
TYR A 251
PRO A 247
SER A 245
LEU A 211
1.72A23.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		4 / 8
TYR A  31
SER A  13
SER A  46
LEU A  45
1.72A17.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wcf NSP3
(SARS-CoV-2)		4 / 8
ASN A 101
ILE A 131
SER A 128
GLY A 130
1.33A
None
MES  A 201 (-4.1A)
MES  A 201 (-4.4A)
MES  A 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wcf NSP3
(SARS-CoV-2)		4 / 8
PRO A 136
SER A 139
SER A 128
GLY A 130
1.51A
None
None
MES  A 201 (-4.4A)
MES  A 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wcf NSP3
(SARS-CoV-2)		4 / 8
ASN A  99
ILE A 131
SER A 128
GLY A 130
1.55A
None
MES  A 201 (-4.1A)
MES  A 201 (-4.4A)
MES  A 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wcf NSP3
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A 101
1.36A
MES  A 201 (-4.1A)
MES  A 201 (-4.4A)
MES  A 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wcf NSP3
(SARS-CoV-2)		4 / 8
SER A 128
GLY A 130
PRO A 136
SER A 139
1.55A
MES  A 201 (-4.4A)
MES  A 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wcf NSP3
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A  99
1.60A
MES  A 201 (-4.1A)
MES  A 201 (-4.4A)
MES  A 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6wen NSP3
(SARS-CoV-2)		3 / 3
SER A 166
ASP A 162
ASN A 159
1.61A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wen NSP3
(SARS-CoV-2)		4 / 8
PRO A 136
SER A 139
SER A 128
GLY A 130
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wey NSP3
(SARS-CoV-2)		4 / 8
ILE A 335
SER A 332
GLY A 334
ASN A 303
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wey NSP3
(SARS-CoV-2)		4 / 8
SER A 332
GLY A 337
PRO A 340
SER A 343
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wey NSP3
(SARS-CoV-2)		4 / 8
PRO A 340
SER A 343
SER A 332
GLY A 334
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wey NSP3
(SARS-CoV-2)		4 / 8
ASN A 303
ILE A 335
SER A 332
GLY A 334
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO D 309
ILE D 337
SER D 318
GLY D 335
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO C 309
ILE C 337
SER C 318
GLY C 335
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO E 302
LEU E 291
ASP E 288
LYS E 355
1.51A16.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO A 309
ILE A 337
SER A 318
GLY A 335
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO D 302
LEU D 291
ASP D 288
LYS D 355
1.60A16.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE A 337
SER A 318
GLY A 335
PRO A 309
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE C 337
SER C 318
GLY C 335
PRO C 309
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE B 337
SER B 318
GLY B 335
PRO B 309
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE D 337
SER D 318
GLY D 335
PRO D 309
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE F 337
SER F 318
GLY F 335
PRO F 309
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO F 309
ILE F 337
SER F 318
GLY F 335
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO E 309
ILE E 337
SER E 318
GLY E 335
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO B 309
ILE B 337
SER B 318
GLY B 335
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE E 337
SER E 318
GLY E 335
PRO E 309
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ILE C7079
PRO C6860
SER C6964
ASN C7008
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		3 / 3
PRO A6878
SER A6872
ASN B4293
1.40A
SAH  A7102 (-3.8A)
SAH  A7102 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ILE A7079
PRO A6860
SER A6964
ASN A7008
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ILE A6838
PRO A6835
SER A7039
SER A7041
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE C 157
SER C  51
PRO C  73
ASN D  77
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO C  73
ASN D  77
ILE C 157
SER C  51
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO A  73
ASN B  77
ILE A 157
SER A  51
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE A 157
SER A  51
PRO A  73
ASN B  77
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP10
NSP16
(SARS-CoV-2)		3 / 3
PRO A6878
SER A6872
ASN B4293
1.34A
SFG  A7103 ( 3.8A)
SFG  A7103 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG800_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP16
(SARS-CoV-2)		4 / 6
MET A6863
ASN C7096
LEU A6892
ASP A6906
1.78A20.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP10
NSP16
(SARS-CoV-2)		3 / 3
PRO C6878
SER C6872
ASN D4293
1.32A
SFG  C7103 ( 3.9A)
SFG  C7103 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP16
(SARS-CoV-2)		4 / 8
ILE A6838
PRO A6835
SER A7039
SER A7041
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP16
(SARS-CoV-2)		4 / 8
ILE A7079
PRO A6860
SER A6964
ASN A7008
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP16
(SARS-CoV-2)		4 / 8
ILE C7079
PRO C6860
SER C6964
ASN C7008
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID800_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP16
(SARS-CoV-2)		4 / 7
MET A6863
ASN C7096
LEU A6892
ASP A6906
1.75A20.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP16
(SARS-CoV-2)		4 / 7
MET A6863
ASN C7096
LEU A6892
ASP A6906
1.79A20.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
SER A 198
ASP A 273
ASN A  74
1.42A
None
EDO  A 408 (-3.0A)
EDO  A 406 (-4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ILE A 236
GLY A 248
PRO A 344
SER A 294
1.66A
None
U5P  A 401 ( 4.5A)
None
U5P  A 401 (-2.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
PRO A 344
SER A 294
ILE A 236
GLY A 248
1.66A
None
U5P  A 401 (-2.7A)
None
U5P  A 401 ( 4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ILE B 236
GLY B 248
PRO B 344
SER B 294
1.65A
None
U5P  B 401 ( 4.4A)
None
U5P  B 401 (-2.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ASP A 273
ASN A  74
SER A 198
1.37A
EDO  A 408 (-3.0A)
EDO  A 406 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ASP A 324
ASN A  75
SER A 198
0.94A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
SER B 198
ASP B 273
ASN B  74
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
PRO B 344
SER B 294
ILE B 236
GLY B 248
1.66A
None
U5P  B 401 (-2.7A)
None
U5P  B 401 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
SER A 198
ASP A 324
ASN A  75
0.95A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ASP B 324
ASN B  75
SER B 198
0.94A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
SER B 198
ASP B 324
ASN B  75
0.94A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ASP B 273
ASN B  74
SER B 198
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PRO B 136
SER B 139
SER B 128
GLY B 130
1.54A
None
None
APR  B 201 (-4.5A)
APR  B 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ILE D 131
SER D 128
GLY D 130
ASN D 101
1.65A
APR  D 201 (-3.8A)
APR  D 201 (-4.3A)
APR  D 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PRO A 136
SER A 139
SER A 128
GLY A 130
1.56A
None
None
APR  A 201 (-4.4A)
APR  A 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER D 128
GLY D 130
PRO D 136
SER D 139
1.58A
APR  D 201 (-4.3A)
APR  D 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER B 128
GLY B 130
PRO B 136
SER B 139
1.59A
APR  B 201 (-4.5A)
APR  B 201 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ILE B 131
SER B 128
GLY B 130
ASN B 101
1.51A
APR  B 201 (-3.3A)
APR  B 201 (-4.5A)
APR  B 201 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PRO D 136
SER D 139
SER D 128
GLY D 130
1.53A
None
None
APR  D 201 (-4.3A)
APR  D 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A 101
ILE A 131
SER A 128
GLY A 130
1.59A
None
APR  A 201 (-3.8A)
APR  A 201 (-4.4A)
APR  A 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ILE C 131
SER C 128
GLY C 130
ASN C 101
1.59A
APR  C 201 (-3.9A)
APR  C 201 (-4.4A)
APR  C 201 (-3.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PRO C 136
SER C 139
SER C 128
GLY C 130
1.54A
None
None
APR  C 201 (-4.4A)
APR  C 201 (-3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER A 128
GLY A 130
PRO A 136
SER A 139
1.61A
APR  A 201 (-4.4A)
APR  A 201 (-3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A 101
1.63A
APR  A 201 (-3.8A)
APR  A 201 (-4.4A)
APR  A 201 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN C 101
ILE C 131
SER C 128
GLY C 130
1.55A
None
APR  C 201 (-3.9A)
APR  C 201 (-4.4A)
APR  C 201 (-3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN B 101
ILE B 131
SER B 128
GLY B 130
1.48A
None
APR  B 201 (-3.3A)
APR  B 201 (-4.5A)
APR  B 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER C 128
GLY C 130
PRO C 136
SER C 139
1.58A
APR  C 201 (-4.4A)
APR  C 201 (-3.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID800_0
(GLUTAMATE RECEPTOR 2)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
SER A6943
ASN A6975
LEU A6978
ASP A6977
1.78A20.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		3 / 3
PRO A6878
SER A6872
ASN B4293
1.35A
SAH  A7101 (-3.9A)
SO4  A7109 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ILE A7079
PRO A6860
SER A6964
ASN A7008
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A 119
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 8
TYR A 305
MET A 244
SER A 245
SER A 262
1.73A23.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A 119
1.77A18.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.66A18.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A  28
SER A 123
SER A 121
GLY A 124
1.67A18.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER A 123
SER A 121
GLY A 124
ASN A  28
1.65A18.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		4 / 8
ILE A  34
PRO A  33
SER A  38
ASN A  37
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		4 / 8
ASN A  37
ILE A  34
PRO A  33
SER A  38
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PRO A 507
SER A 443
ASN A 501
GLY A 496
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
ILE B  34
PRO B  53
SER B  56
SER B  71
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ILE E 332
PRO E 330
SER E 366
PRO E 527
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
PRO H 130
PRO H 217
SER H 192
GLY H 194
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
TYR H 149
PRO H 171
SER H 183
LEU H 182
1.55A23.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
PRO B 105
ILE B 102
SER B 100
GLY B 101
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
PRO H 217
SER H 192
GLY H 194
PRO H 130
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
TYR B 149
PRO B 171
SER B 183
LEU B 182
1.54A23.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
(Homo
sapiens)		3 / 3
PRO B 123
SER B 207
ASN B 203
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
ILE B  30
SER B  75
SER L 174
ASN B  77
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
PRO H 105
ILE H 102
SER H 100
GLY H 101
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
ILE H  34
PRO H  53
SER H  56
SER H  71
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
GLY A 496
PRO A 507
SER A 443
ASN A 501
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6yla LIGHT CHAIN
(Homo
sapiens)		3 / 3
ASP C 176
ASN C 144
SER C 174
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
ILE H  34
PRO H  53
SER H  56
SER H  71
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
SER L 174
ASN B  77
ILE B  30
SER B  75
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
SER B 183
GLY B 143
SER C 182
ASN C 143
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
SER C 182
ASN C 143
SER B 183
GLY B 143
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ILE E 332
PRO E 330
PRO E 527
SER E 366
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
SER A 514
ASP A 398
ASN A 354
1.62A
None
None
PG0  A 902 ( 4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
ILE B 102
SER B 100
GLY B 101
PRO B 105
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
ILE H 102
SER H 100
GLY H 101
PRO H 105
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6yla LIGHT CHAIN
(Homo
sapiens)		3 / 3
SER C 174
ASP C 176
ASN C 144
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PRO E 527
SER E 366
ILE E 332
PRO E 330
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
ILE B  34
PRO B  53
SER B  56
SER B  71
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASP A 398
ASN A 354
SER A 514
1.63A
None
PG0  A 902 ( 4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 8
PRO H 130
PRO H 217
SER H 192
GLY H 194
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 8
ILE H 102
SER H 100
GLY H 101
PRO H 105
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 8
PRO H 105
ILE H 102
SER H 100
GLY H 101
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 8
ILE H  34
PRO H  53
SER H  56
SER H  71
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 8
PRO H 217
SER H 192
GLY H 194
PRO H 130
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 8
TYR H 149
PRO H 171
SER H 183
LEU H 182
1.51A23.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 8
ILE H  34
PRO H  53
SER H  56
SER H  71
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER A 147
GLY A 143
SER A 123
ASN A  28
1.63A
None
P6N  A 502 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER A 123
ASN A  28
SER A 147
GLY A 143
1.63A
None
None
None
P6N  A 502 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
TYR E 453
PRO B  14
SER B  85
LEU E 455
1.73A22.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
ILE H  34
PRO H  53
SER H  56
SER H  71
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
PRO H 105
ILE H 102
SER H 100
GLY H 101
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
PRO B 217
SER B 192
GLY B 194
PRO B 130
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
ILE B  34
PRO B  53
SER B  56
SER B  71
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
ILE B 102
SER B 100
GLY B 101
PRO B 105
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
PRO H 217
SER H 192
GLY H 194
PRO H 130
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
PRO B 105
ILE B 102
SER B 100
GLY B 101
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
ILE B  34
PRO B  53
SER B  56
SER B  71
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
ILE H  34
PRO H  53
SER H  56
SER H  71
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
TYR H 149
PRO H 171
SER H 183
LEU H 182
1.54A23.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
TYR B 149
PRO B 171
SER B 183
LEU B 182
1.56A23.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
PRO H 130
PRO H 217
SER H 192
GLY H 194
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
GLY E 496
PRO E 507
SER E 443
ASN E 501
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
ILE H 102
SER H 100
GLY H 101
PRO H 105
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
PRO B 130
PRO B 217
SER B 192
GLY B 194
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A 119
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER B 166
ASP B 162
ASN B 159
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER C 166
ASP C 162
ASN C 159
1.59A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP E 162
ASN E 159
SER E 166
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER D 166
ASP D 162
ASN D 159
1.61A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP A 162
ASN A 159
SER A 166
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER C  84
ASP D 157
ASN D  20
1.13A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP D 157
ASN D  20
SER C  84
1.12A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER E   5
ASP D  14
ASN D  15
1.17A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE B 131
SER B 128
GLY B 130
ASN B  99
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO D 136
SER D 139
SER D 128
GLY D 130
1.66A
None
None
None
EDO  D 205 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO C 136
SER C 139
SER C 128
GLY C 130
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN B  99
ILE B 131
SER B 128
GLY B 130
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN B 101
ILE B 131
SER B 128
GLY B 130
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN C 101
ILE C 131
SER C 128
GLY C 130
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER C  84
ASP D 157
ASN D  20
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER A 166
ASP A 162
ASN A 159
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN C  99
ILE C 131
SER C 128
GLY C 130
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO A 136
SER A 139
SER A 128
GLY A 130
1.68A
None
None
EDO  A 202 (-4.3A)
EDO  A 202 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER E 166
ASP E 162
ASN E 159
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP B 162
ASN B 159
SER B 166
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP D  14
ASN D  15
SER E   5
1.28A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO E 136
SER E 139
SER E 128
GLY E 130
1.68A
None
None
EPE  E 202 (-4.6A)
EPE  E 202 ( 4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER E 128
GLY E 130
PRO E 136
SER E 139
1.60A
APR  E 201 (-4.4A)
APR  E 201 (-3.2A)
EDO  B 202 (-4.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER B 128
GLY B 130
PRO B 136
SER B 139
1.58A
APR  B 201 (-4.3A)
APR  B 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO B 136
SER B 139
SER B 128
GLY B 130
1.53A
None
None
APR  B 201 (-4.3A)
APR  B 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE D 131
SER D 128
GLY D 130
ASN D 101
1.54A
APR  D 201 (-3.4A)
APR  D 201 (-4.3A)
APR  D 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER C 128
GLY C 130
PRO C 136
SER C 139
1.57A
APR  C 201 (-4.4A)
APR  C 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A 101
1.56A
APR  A 201 (-3.1A)
APR  A 201 (-4.4A)
APR  A 201 ( 3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO D 136
SER D 139
SER D 128
GLY D 130
1.53A
None
None
APR  D 201 (-4.3A)
APR  D 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE E 131
SER E 128
GLY E 130
ASN E 101
1.57A
APR  E 201 (-3.4A)
APR  E 201 (-4.4A)
APR  E 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER A 166
ASP A 162
ASN A 159
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER B 166
ASP B 162
ASN B 159
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE B 131
SER B 128
GLY B 130
ASN B 101
1.55A
APR  B 201 (-3.2A)
APR  B 201 (-4.3A)
APR  B 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER C 166
ASP C 162
ASN C 159
1.56A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP D  14
ASN D  15
SER E   5
1.28A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP C 162
ASN C 159
SER C 166
1.58A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER C  84
ASP D 157
ASN D  20
1.12A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE C 131
SER C 128
GLY C 130
ASN C 101
1.58A
APR  C 201 (-3.3A)
APR  C 201 (-4.4A)
APR  C 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP B 162
ASN B 159
SER B 166
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER D 128
GLY D 130
PRO D 136
SER D 139
1.57A
APR  D 201 (-4.3A)
APR  D 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER D 166
ASP D 162
ASN D 159
1.58A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN B 101
ILE B 131
SER B 128
GLY B 130
1.53A
None
APR  B 201 (-3.2A)
APR  B 201 (-4.3A)
APR  B 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO C 136
SER C 139
SER C 128
GLY C 130
1.53A
None
None
APR  C 201 (-4.4A)
APR  C 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP D 162
ASN D 159
SER D 166
1.59A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO E 136
SER E 139
SER E 128
GLY E 130
1.55A
EDO  B 202 (-4.7A)
None
APR  E 201 (-4.4A)
APR  E 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP D 157
ASN D  20
SER C  84
1.11A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER A 128
GLY A 130
PRO A 136
SER A 139
1.59A
APR  A 201 (-4.4A)
APR  A 201 ( 3.2A)
EDO  A 205 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN E 101
ILE E 131
SER E 128
GLY E 130
1.52A
None
APR  E 201 (-3.4A)
APR  E 201 (-4.4A)
APR  E 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP E 162
ASN E 159
SER E 166
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP A 162
ASN A 159
SER A 166
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER E 166
ASP E 162
ASN E 159
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER E   5
ASP D  14
ASN D  15
1.17A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO A 136
SER A 139
SER A 128
GLY A 130
1.54A
EDO  A 205 ( 4.9A)
None
APR  A 201 (-4.4A)
APR  A 201 ( 3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN C  99
ILE C 131
SER C 128
GLY C 130
1.66A
None
MES  C 201 (-4.0A)
MES  C 201 (-4.6A)
MES  C 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER C 128
GLY C 130
PRO C 136
SER C 139
1.58A
MES  C 201 (-4.6A)
MES  C 201 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A 101
1.46A
MES  A 201 (-4.8A)
MES  A 201 (-4.4A)
MES  A 201 (-3.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN A 101
ILE A 131
SER A 128
GLY A 130
1.42A
None
MES  A 201 (-4.8A)
MES  A 201 (-4.4A)
MES  A 201 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN A  99
ILE A 131
SER A 128
GLY A 130
1.56A
None
MES  A 201 (-4.8A)
MES  A 201 (-4.4A)
MES  A 201 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER A 128
GLY A 130
PRO A 136
SER A 139
1.56A
MES  A 201 (-4.4A)
MES  A 201 (-3.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER A 166
ASP A 162
ASN A 159
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO A 136
SER A 139
SER A 128
GLY A 130
1.51A
None
None
MES  A 201 (-4.4A)
MES  A 201 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO B 136
SER B 139
SER B 128
GLY B 130
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN C 101
ILE C 131
SER C 128
GLY C 130
1.48A
None
MES  C 201 (-4.0A)
MES  C 201 (-4.6A)
MES  C 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER A 166
ASP A 162
ASN A 159
1.39A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP A 162
ASN A 159
SER A 166
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO C 136
SER C 139
SER C 128
GLY C 130
1.53A
None
None
MES  C 201 (-4.6A)
MES  C 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER C 166
ASP C 162
ASN C 159
1.57A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A  99
1.60A
MES  A 201 (-4.8A)
MES  A 201 (-4.4A)
MES  A 201 (-3.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE802_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP A 162
ASN A 159
SER A 166
1.37A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE C 131
SER C 128
GLY C 130
ASN C 101
1.53A
MES  C 201 (-4.0A)
MES  C 201 (-4.6A)
MES  C 201 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		7bqy MAIN PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
PRO A 227
ASN A 198
ILE A 201
GLY A 230
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
ILE A 201
GLY A 230
PRO A 227
ASN A 198
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
PRO A 378
PRO A 328
SER A 664
GLY A 327
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 8
SER A 397
PRO B 121
SER A 672
GLY A 385
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 8
PRO B 121
SER A 672
GLY A 385
SER A 397
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
PRO A 537
PRO A 328
SER A 664
GLY A 327
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
MET A 633
SER A 635
LEU A 308
ASP A 304
1.72A14.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
ILE A 201
SER A 229
GLY A 200
PRO A 232
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
ILE A 539
PRO A 378
SER A 664
PRO A 537
1.06A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
PRO A 232
ILE A 201
SER A 229
GLY A 200
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
PRO A 537
ILE A 539
PRO A 378
SER A 664
1.07A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
SER A 123
ASN A  28
SER A 147
GLY A 143
1.58A
None
None
None
JRY  A 401 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
SER A 147
GLY A 143
SER A 123
ASN A  28
1.60A
None
JRY  A 401 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PRO A 537
ILE A 539
PRO A 378
SER A 664
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
MET A 633
SER A 635
LEU A 308
ASP A 304
1.49A14.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ILE A 539
PRO A 378
SER A 664
PRO A 537
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
PRO A 243
SER A 239
ASN A 312
1.23A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7bv1 NSP12
NSP8
(SARS-CoV-2)		4 / 8
PRO B 121
SER A 672
GLY A 385
SER A 397
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ILE A 201
SER A 229
GLY A 200
PRO A 232
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7bv1 NSP12
NSP8
(SARS-CoV-2)		4 / 8
SER A 397
PRO B 121
SER A 672
GLY A 385
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ILE A 201
SER A 229
GLY A 200
PRO A 232
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB800_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
TYR A 530
LEU A 527
PRO A 505
SER A 564
GLY A 503
1.59A14.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID800_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 7
ASN B 109
LEU A 271
ASP A 269
LYS A 272
1.79A18.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ILE A 201
GLY A 230
PRO A 227
ASN A 198
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ILE A 539
PRO A 378
SER A 664
PRO A 537
1.03A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
PRO A 243
SER A 239
ASN A 312
1.25A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PRO A 232
ILE A 201
SER A 229
GLY A 200
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PRO A 227
ASN A 198
ILE A 201
GLY A 230
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
MET A 756
SER A 759
LEU A 758
ASP A 761
1.77A14.87
None
U  P  20 ( 2.8A)
None
MG  P 101 (-3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PRO A 537
PRO A 328
SER A 664
GLY A 327
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PRO A 537
ILE A 539
PRO A 378
SER A 664
1.04A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
MET A 633
SER A 635
LEU A 308
ASP A 304
1.66A14.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ILE A 536
PRO A 537
SER A 343
PRO A 378
1.68A
None